Announced details
The company is conducting joint research with the Department of Ophthalmology, Faculty of Medicine, The University of Tokyo. Partnership discussions with pharmaceutical companies are ongoing. No specific contract has been stated as having been signed.
The Department of Ophthalmology, Faculty of Medicine, The University of Tokyo, and numerous pharmaceutical companies in Japan and overseas. Locations, representatives, capital, year of establishment and other details are not disclosed.
The company stated that it aims to stabilize its earnings structure through the out-licensing of RBM-007 and the acquisition of projects for its drug discovery support business, but the specific impact on earnings has not been disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | RBM-007, RBM-006, RBM-011, DDS aptamers |
| Counterparty | Department of Ophthalmology, Faculty of Medicine, The University of Tokyo, and numerous pharmaceutical companies in Japan and overseas (specific names not disclosed) |
| Counterparty overview | The Department of Ophthalmology, Faculty of Medicine, The University of Tokyo, and numerous pharmaceutical companies in Japan and overseas. Locations, representatives, capital, year of establishment and other details are not disclosed. |
| Relationship with the Company | The company is conducting joint research with the Department of Ophthalmology, Faculty of Medicine, The University of Tokyo. Partnership discussions with pharmaceutical companies are ongoing. No specific contract has been stated as having been signed. |
| Applicable area | Achondroplasia (ACH), Diabetic macular edema (DME), Glaucoma, Diabetic retinopathy |
| Impact on Business Performance | The company stated that it aims to stabilize its earnings structure through the out-licensing of RBM-007 and the acquisition of projects for its drug discovery support business, but the specific impact on earnings has not been disclosed. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To disclose the questions received at the Annual General Meeting of Shareholders and the answers in the order in which the questions were asked.